Global Non-Oncology Precision Medicine Market-By Products (Diagnostics, Therapeutics), By Application (Oncology, CNS, Immunology, Respiratory, Infectious Diseases, Neurology, Others), By End-User (Hospitals, Diagnostics Center, Research & Academic Institutes, Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2024-2033

Report Overview

The Global Non-Oncology Precision Medicine Market size is expected to be worth around USD 192.1 Billion by 2033 from USD 76.8 Billion in 2023, growing at a CAGR of 9.6% during the forecast period from 2024 to 2033.

Precision medicine involves an approach towards patient care depending upon the idea that a condition of patient suffering immunodeficiency disorder, cancer or any genetic disorder is not same in every individual. The environmental factors coupled with the inherited genes impacts one’s health and symptoms of the disorder. Thus, treatment may vary from person to person. Precision medications attempts to understand how health is influenced by varying genes. Cancer conditions mostly make use of precision medicine.

However, owing to research and technological advancements, precision medicines are now utilized to treat diverse chronic diseases and disorders. Some of the most common chronic illnesses include depression, chronic obstructive pulmonary disease, chronic kidney disorder, coronary heart disease, Alzheimer’s disease, dementia and high cholesterol.

• According to World Health Organization, around 50 million or more individuals are suffering from dementia and same number of individuals are fighting with epilepsy. From this number, approximately 60% to 70% are the cases of Alzheimer’s.

The market for non-oncology precision medicines is majorly driven by rising prevalence of respiratory and infectious diseases combined with growing investments by major industry players. Based on numbers, precision medicines in the market was 5 in 2005, with gradual increase to 81 in 2012, 132 in 2016 followed by a massive growth of 286 precision medicines in 2020.

• Non-oncology precision medicine market witnessed 4 funding and investments, 59 collaborations and partnerships, 44 product launches, 18 mergers and acquisitions, 29 regulatory and legal activities and 6 business expansions.

Key Takeaways

• Based on product, the market for non-oncology precision medicines is dominated by therapeutics segment capturing a massive revenue share of 74.6% in the year 2023.
• Based on application, CNS segment ruled the non-precision medicines market securing an impressive market share of 29.5%.
• Based on end use, diagnostic centers came up as the frontrunner in the global non-oncology precision medicines market.
• The market is vigorously thriven by rising demand for precision medicines for treating diverse medical conditions including cardiovascular disorders, respiratory issues and diabetes.
• Ethical and legal concerns can hamper the market in near future.

By Product Analysis

Therapeutics segment dominates the market

Based on product, the market is broadly categorized into diagnostics and therapeutics. Amongst both the segments, therapeutics is a major leader in the global non oncology precision medicine market. Therapeutics segment is accounted to hold a significant market revenue share of 74.6% dominating the market in the year 2023. The significance of therapeutics segment is underscored due to continuous developments in non-oncology therapeutics for diverse medical conditions including malignant growth, and hereditary infections.

Apart from this, scientists across various nations are emphasized in incorporating advancements related to designated treatments for conditions like cardiovascular sicknesses, irresistible infections and gastroenterology. The segmental growth is further accelerated by virtue of advancement of novel medications combined with escalating utilization of medications in non-oncology precision medicine treatment plans.

• According to VMG Health’s Multispecialty ASC Benchmarking Study 2022, Gastroenterology is the most represented specialty among ambulatory surgical centers, making up 32% of all cases.
• According to America Heart Association, cardiovascular illnesses being a leading cause of death, accounted for 928,741 deaths in 2020.

By Application Analysis

CNS marks the major market growth

Based on applications, the market is segmented into Oncology, CNS, Immunology, Respiratory, Infectious Diseases, Neurology and other segments. A substantial market revenue shares of 29.5% is withheld by CNS segment dominating the non-oncology precision medicine market in the year 2023. The predominance of the segment is highly ascribed to the rising incidences of CNS problems including epilepsy, different sclerosis, and Alzheimer’s disease across the globe.

Many major industry players such as Novartis AG and Pfizer are associated with advancements of designated treatments for treating diverse sensory system conditions. The highlight on development of treatment for designated conditions coupled with amelioration of customized clinical treatment plans for individuals affected with CNS problems further encourage the business dimensions.

• According to World Health Organization, approximately 50 to 52 million of individuals across the globe deals with epilepsy. The number of cases exceeding 50 million experiences ill effects of dementia. In addition, 60-70% of the cases comprises of Alzheimer’s disease, considered as a most normal type of dementia.

By End User Analysis

Diagnostic centers form the center stage

Based on end use, the market fractionated into Hospitals, Diagnostics Center, Research & Academic Institutes and others. A massive market revenue shares of 45.6% is captured by diagnostic center segment owing to the significance of prescient diagnostic testing. The segment holds a growing business due to developments in symptomatic methods and groundbreaking framework providing most ideal type of assistance towards patient population.

Furthermore, the escalating recognition among patient populace related to the importance of diagnostics, developing interest in prescient indicative testing for disease, hereditary problems and pneumonic issues among other opens up new growth pathways for the non-oncology precision medicine market.

Key Market Segments

By Product

• Diagnostics
• Therapeutics

By Application

• Oncology
• CNS
• Immunology
• Respiratory
• Infectious Diseases
• Neurology
• Other

By End User

• Hospitals
• Diagnostics Center
• Research & Academic Institutes
• Others

Market Drivers

Rising ultimatum for precision medicines

The market for non-oncology precision medicine is majorly driven by growing demand for personalized medicines in recent years. The idea of personalized medications offers more tailored fit addressing specific individuals’ conditions, thereby providing efficient therapeutic options. Targeted therapies and interventions comprising higher efficacy and lower side effects are developed by scrutinizing specific molecular targets and biomarkers of an individual. Personalized medicines assists in early detection, prevention and management of disease.

For instance, when a genetic testing is conducted for a person dealing with cardiovascular illnesses, it allows to identify conditions associating higher risks including hypertension and dyslipidemia. Depending upon this insight, healthcare professionals can implement lifestyle modifications, prescribe appropriate medications and closely monitor the individuals to prevent of delay disease progression.

• Every 33 seconds, 1 person dies due to cardiovascular disease in United States, resulting in approximately 695,000 deaths in 2021.

Personalized medicine approach is being employed for neurological conditions including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis. The diseases can be diagnosed at the onset stage resulting into the development of targeted therapies addressing specific underlying molecular mechanisms of related diseases. Thus, this represents the growing interest of personalized medicines in pharmaceutical firms, thereby excelling the market dimensions for non-oncology precision medicines.

• In 2022, 12 personalized medicines were identified and approved, accounting for approximately 34 percent of all newly approved drugs.

Ongoing advancements further pushes the market

The ongoing advancements in genomic technologies including single cell sequencing, epigenetic profiling, and long read sequencing strongly pushes the market in an optimistic growth. By adopting advanced genomic technologies, the provision of personalized and tailored medical treatments is largely done, enhancing precision medicine approaches. Thus, a deeper insight into cellular processes, disease mechanism and gene regulation enable more precise diagnosis, prognosis and treatment selection, fueling the market expansion.

• In January 2023, Apollo Hospitals Navi Mumbai, India, introduced Apollo genomic institute with the aim to deliver holistic care to individuals and families impacted by genetic disorders.

Market Restraints

Ethical & Legal concerns

A major impediment is caused obstructing the non-oncology precision medicine market growth by ethical and legal challenges. As the process of precision medicines require collection, storage, analysis, and sharing of genetic and personal health information, there arises concerns regarding patient privacy, data security, informed consent, and potential misuse of sensitive information. A psychological distress is created among patients by virtue of data breaches, unauthorized access or misuse of genetic data.

High cost of targeted therapies

The market may further impede due to the risk of exacerbating health disparities and inequities in access to precision medicine. Not every individual can afford genetic testing and targeted therapies due to its high cost, thus generating disparities in healthcare outcomes.

Opportunities

Integration of AI-based technologies offers wealthy opportunities

Excellent growth opportunities are provided for the industry players operating in non-oncology precision medicine market by virtue of integrating artificial intelligence and machine learning in non-oncology precision medicine. This led to potential transformation of healthcare by analyzing large-scale genomic data, clinical records, and real-time patient monitoring, generating actionable perceptions, thereby supporting real time decision marking.

Identification of patterns, correlations and predictive models is precisely done by AI algorithms aiding in diagnosis of disease, risk assessment, and treatment selection. Thus, more accurate and precise personalized recommendations are generated by AI-powered systems. The market further propels due to rising healthcare spending, rising recognition of precision medicine, and government initiatives promoting personalized healthcare, thereby creating a favorable market environment.

Growing geriatric population

The growing elderly population are more prone to chronic illnesses including respiratory diseases, cardiovascular disorders and diabetes. Thus, this necessitates the demand for precision medicine for more effective and long-term efficiency of treatment towards these vital diseases. Thus, this creates opportunities for the pharmaceutical industries to develop more effective precision medicines, thereby contributing to market growth.

According to World Health Organization, 1 in every 6 individuals will be 60 years and above by 2030

Impact of macroeconomic factors

One of the significant macroeconomic factor influencing the market spread is rising inflation affecting the prices of precision medicines, consumer purchasing power, and cost of regulatory compliance. The rising inflation affects the pricing of these non-oncology precision medications, making the companies to adjust their pricing to conceal heightening operational costs. This limits the patients and healthcare providers’ access towards advanced precision medicines.

Consumers and healthcare professionals find it more difficult to afford such expensive precision medicine solutions, slowing down the adoption rate particularly in the regions where patients have limited accessibility for insurance coverage for highly improved medical treatments.

Latest Trends

Cardiovascular precision medicine: The diagnosis and treatment of cardiovascular diseases is revolutionized due to precision medicines. Higher risk of developing conditions including arrhythmias, cardiomyopathies, and coronary artery disease can be accurately scrutinized by genetic testing.

Precision Psychiatry: The application of precision medicine in the field of psychiatry has led to precise diagnosis and treatment of mental health disorders. Treatments for conditions including depression and bipolar disorder can be tailored through genetic testing in combination with biomarkers and clinical data.

Regional Analysis

North America to witness significant growth during the forecast period

North America is a leader in global non-oncology precision medicine market encapsulating a remarkable revenue share of 31.6% in the year 2023, with United States as a major market share holder. The regional growth is highly attributed to the strong healthcare infrastructure, presence of worthy industry players, heightening prevalence of chronic disorders and significant investment in precision medicine research.

United States witnessed a rise in public and private initiatives aimed at advancing precision medicines. For instance, US government launched a precision medicine initiative to accelerate the development and adoption of precision medicine approaches across various disease areas.

• In May 2023, a US-based Intergovernmental organization estimated that Chronic diseases such as cardiovascular diseases, diabetes, cancer, and respiratory illnesses accounted for 86% of 90 million deaths by 2050.

Asia-Pacific, in addition witnessed fastest growth in non-oncology precision medicines market owing to China, as a major contributor to growth thriven by rising healthcare spending and government initiatives promoting precision medicines.

By Region

• North America
  • The US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia & CIS
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • ASEAN
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • UAE
  • Rest of MEA

Key Players Analysis

There are various companies that manufacture products or launch new techniques for Non-Oncology Precision Medicine such as Novo Nordisk, GE healthcare, Alphabet Inc, Sanofi, and Tempus, etc.

In order to expand the footprints into the market these companies develop various strategies. These market developments include new product launches, contractual agreements, high investments, unifications and acquisitions, alliance with other organizations. Cost effective products is one of the eye catching tactic to expand and survive in rising market climate. In addition, the product approvals by regulatory authorities further stretch the market to a noticeable reach during the forecast period.

• According to Personalized Medicine Coalition in 2022, 12 personalized medicines were approved by US Food & Drug Administration, accounted for 34 to 26% of all newly approved therapeutic molecular entities.

Key Market Players

• Pfizer Inc.
• Abbott Laboratories
• Medtronic
• Novartis
• Eli Lilly & Company
• Laboratory Corporation of America Holdings
• Qiagen, Inc.
• Quest Diagnostics Inc.
• Bristol Myers Squibb
• Danaher Corporation

Recent Developments

• In June 2021: Weill Cornell Medicine announced, ‘We are Changing Medicine’, campaign wirth USD 1.5 billion aiming to advance biomedical innovations in areas such as artificial intelligence, Precision medicine, machine learning, and genomics.
• In July 2019: Pfizer cooperated with Synapse, to fuel malignant growth research. The joint effort was meant to zero in on sub-atomic testing and treatment decisions on non-oncology precision medicine accordingly expanding the product portfolio.

Report Scope